Progress of Treatment in Recurrent Ovarian Cancer with Trabectedin
ZHAO Jian-guo
QU Peng-peng
Abstract：Trabectedin (Yondelis R ) is a new non-platinum antineoplastic drug with a unique antitumor mechanism. It′s main side effect is the reversible liver injury, and it′s cardiac toxicity is low. Trabectedin can be applied with anthracycline-based drugs in the treatment of recurrent ovarian cancer. The optional treatment clinically include:single drug 3 weeks plan, single drug weekly therapy,combined anthracycline-based drugs,the best effect is the in combinational scheme. Trabectedin make satisfied curative effect in platinum sensitive recurrent ovarian cancer ,especially treatment-free interval (TFI) 6-12 month. The platinum resistance and refractory ovarian cancer curative effect is not obvious. Application of Trabectedin can extend the TFI ,as to create conditions for using platinum drugs again.
Keywords：Ovarian neoplasmsCarcinomaAntineoplastic combined chemotherapy protocolsTrabectedinPlatinum-free interval
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 240-243 )